vepdegrestrant   Click here for help

GtoPdb Ligand ID: 11511

Synonyms: ARV-471 | ARV471 | compound 341 [WO2018102725A1] | PF-07850327 | PF07850327
Compound class: Synthetic organic
Comment: Vepdegrestrant (ARV471) is a bifunctional compound that is estrogen receptor (ER) degrader (PROTAC) [1]. It uses a cereblon-based binder to direct ER protein degradation. ARV471 is orally bioavailable, and is being investigated for potential to treat breast cancer.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 96.43
Molecular weight 723.38
XLogP 7.16
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C1CCC(C(=O)N1)N1Cc2c(C1=O)ccc(c2)N1CCN(CC1)CC1CCN(CC1)c1ccc(cc1)[C@H]1[C@H](CCc2c1ccc(c2)O)c1ccccc1
Isomeric SMILES O=C1CCC(C(=O)N1)N1Cc2c(C1=O)ccc(c2)N1CCN(CC1)CC1CCN(CC1)c1ccc(cc1)[C@H]1[C@H](CCc2c1ccc(c2)O)c1ccccc1
InChI InChI=1S/C45H49N5O4/c51-37-12-15-39-33(27-37)8-13-38(31-4-2-1-3-5-31)43(39)32-6-9-35(10-7-32)48-20-18-30(19-21-48)28-47-22-24-49(25-23-47)36-11-14-40-34(26-36)29-50(45(40)54)41-16-17-42(52)46-44(41)53/h1-7,9-12,14-15,26-27,30,38,41,43,51H,8,13,16-25,28-29H2,(H,46,52,53)/t38-,41?,43+/m1/s1
InChI Key TZZDVPMABRWKIZ-MFTLXVFQSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Crew AP, Qian Y, Dong H, Wang J, Hornberger KR, Crews CM. (2018)
Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders.
Patent number: WO2018102725A1. Assignee: Arvinas Inc.. Priority date: 01/12/2016. Publication date: 07/06/2018.
2. Hamilton EP, Ma C, De Laurentiis M, Iwata H, Hurvitz SA, Wander SA, Danso M, Lu DR, Perkins Smith J, Liu Y et al.. (2024)
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer.
Future Oncol, 20 (32): 2447-2455. [PMID:39072356]